PROCEPT BioRobotics Corporation reported strong financial results for the first quarter ended March 31, 2025, with total revenue increasing 55% year-over-year to $69.2 million. U.S. revenue grew 50% to $60.3 million, driven by system sales to new hospital customers and a 61% increase in U.S. handpiece and consumable revenue to $38.0 million.
The company's gross margin expanded to 64% in Q1 2025, up from 56% in the prior year period, attributed to improved operational efficiencies, overhead absorption, and higher average selling prices on U.S. robotic systems. The net loss narrowed to $24.7 million from $26.0 million, and Adjusted EBITDA loss improved to $15.8 million from $20.4 million.
PROCEPT BioRobotics increased its full-year 2025 revenue guidance to approximately $323 million, reflecting continued strong procedural momentum and confidence that the saline disruption is behind them. The U.S. launch of the HYDROS system continues to build momentum, with approximately 45% of U.S. system placements in Q1 coming from corporate IDN multi-unit orders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.